Received Oct 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | 3052734 | IM |
| FLU3 | INFLUENZA (SEASONAL) (AFLURIA) | SEQIRUS, INC. | UNK | AX4605A | IM / RA |
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | UNK | MA2519 | IM / LA |
Patient received PCV 20 on 9/24, Afluria on 9/26, and Moderna vaccine on 10/1. Reported weakness and functional decline during therapy and needing more assistance overall. UA/CS and CBC/CMP completed were unremarkable. Resident evaluated by Physiatrist and sent out for evaluation to hospital. Suspicion for either vaccine related illness or neurological illness.
WEAKNESS OF THE LOWER EXTREMITIES, LOCALIZED EDEMA, CHRONIC SYSTOLIC (CONGESTIVE) HEART FAILURE
PERIPHERAL VASCULAR DISEASE, Dementia, Atherosclerotic heart disease, TIA, hyperlipidemia, ischemic cardiomyopathy, cerebrovascular disease
Probiotic Oral Capsule 250 MG, Aspirin EC Tablet Delayed Release 81 MG, Lisinopril Oral Tablet 5 MG, Multi-Vitamin Oral Tablet, Atorvastatin Calcium Oral Tablet 10 MG, Carvedilol Oral Tablet 3.125 MG, Vitamin D3 Oral Capsule 50 MCG (2000 UT
Tylenol
Urinalysis 10/3/2025, CBC 10/3/2025, CMP 10/3/2025